Direct compression of Zhichuan Injection Veterinary Grade API into veterinary tablet cores is constrained by the injection-grade particle-size distribution rather than by chemical potency alone. The as-received powder typically carries a low microbial bioburden because it is controlled for parenteral production, but the sieve fraction above 200 µm must be reduced before die fill on a rotary tablet press. A conical mill fitted with a 0.5 mm screen and operated at 2,000–2,500 rpm brings the d90 below 180 µm while limiting fines generation below 45 µm to avoid capping at high press speed. The processed API is blended with microcrystalline cellulose at 30–50% w/w, lactose monohydrate at 20–40% w/w, crospovidone at 2–5% w/w, and magnesium stearate at 0.5–1.0% w/w in a bin blender for 15–25 min at 60–75% vessel fill. Dry blending is preferred when the API shows acceptable flow; if the Carr index exceeds 25, a wet granulation route with starch paste at 5–8% w/w is substituted. Compaction on a 16–27 station rotary press is operated at main compression force 8–20 kN, precompression 2–5 kN, and turret speed 30–60 rpm. Tablet hardness is maintained at 50–100 N and thickness variation below ±3%. Friability is tested according to Ph. Eur. 2.9.7 or USP <1216>; the acceptance limit is ≤1.0% after 100 revolutions. Disintegration in water at 37±2°C follows Ph. Eur. 2.9.1 and should be complete within 15 min for immediate-release veterinary tablets unless the target species requires a flavoured or film-coated variant, in which case the coating must not extend disintegration beyond the registered specification. The terminal products are typically 50 mg, 100 mg, and 250 mg scored tablets packed in high-density polyethylene jars with desiccant.

What Limits Sterile Filtration Flux in High-Concentration Aqueous Injection Batches?

For aqueous injections containing Zhichuan Injection Veterinary Grade API, the limiting process parameter is often the prefiltration particle load when the formulation is compounded above 100 mg/mL. The injection-grade raw material is dissolved in Water for Injections at 20–30°C under low-shear mixing; pH is then adjusted with dilute hydrochloric acid or sodium hydroxide to a registered stability window, frequently pH 3.5–6.5 for weakly basic or weakly acidic veterinary actives. Tonicity is corrected with sodium chloride to 0.65–0.9% w/v and target osmolality of 280–330 mOsm/kg. Prefiltration through a 0.45 µm polyethersulfone membrane protects the sterilizing-grade 0.22 µm membrane and reduces flux decay caused by colloidal aggregation. Filter integrity is verified before and after filling by bubble point or pressure decay; the pass value is taken from the filter validation file and commonly exceeds 3.0 bar for a water-wet 0.22 µm polyethersulfone membrane. The sterile-filtered solution is filled into Type I glass vials of 10 mL or 50 mL nominal volume under Grade A unidirectional airflow defined in EU GMP Annex 1 and ISO 14644-1 Class 5, then stoppered with bromobutyl rubber closures and capped. If the API is thermostable, terminal sterilisation at 121°C with F0≥15 min is applied; otherwise aseptic processing is mandatory and requires media-fill validation at intervals not exceeding 6 months. The finished injection is tested for particulate matter according to USP <788> or Ph. Eur. 2.9.19: for small-volume parenterals, the light obscuration count is limited to 6,000 particles per container at ≥10 µm and 600 particles per container at ≥25 µm. Sterility testing follows Ph. Eur. 2.6.1 or USP <71> using membrane filtration of the entire container contents. Bacterial endotoxin testing follows Ph. Eur. 2.6.14; a typical veterinary injectable limit is ≤0.5 EU/mg unless the registered specification is lower. The terminal product is intended for subcutaneous, intramuscular, or intravenous administration according to the veterinary marketing authorisation; multidose vials require a preservative efficacy test per Ph. Eur. 5.1.3 or USP <51>.

Because capsule-filling lines impose a narrower flow window than direct compression, the Zhichuan Injection Veterinary Grade API is pre-blended with colloidal silicon dioxide before transfer to the dosing station. The pre-blend step uses 0.5–1.5% w/w of colloidal silicon dioxide and 10–30% w/w of pregelatinized starch to raise the bulk density into the 0.45–0.65 g/mL range that prevents dosator nozzle overfill or underfill. The machine is a dosator-type capsule filler or tamping-pin filler operating at 25,000–75,000 capsules/hour depending on size and powder bed uniformity. Final lubrication with magnesium stearate is limited to 0.25–0.5% w/w; higher concentrations can delay capsule shell disintegration and reduce release rate. Hard gelatin or HPMC capsules in sizes 0, 1, and 2 are filled to a target weight variation of ±5% for individual capsules. Content uniformity follows Ph. Eur. 2.9.40 or USP <905>; the acceptance value is ≤15 unless the dosage form is a fixed-dose combination, in which case the stricter acceptance value may apply. Disintegration in 900 mL water at 37±2°C is complete within 30 min under Ph. Eur. 2.9.1. If enteric or delayed-release capsules are registered for certain companion-animal indications, the film-coating polymer and plasticizer ratio must be validated in dissolution media at pH 1.2 and pH 6.8 according to Ph. Eur. 2.9.3 or USP <711>. Terminal packages are cold-seal aluminium blisters with polyvinyl chloride base film and paper-foil lidding to limit moisture ingress below 0.5 mg/day per blister.

When the API’s Particle-Size Distribution Demands Torque-Controlled Granulation Endpoints

The transition from powder blend to granule form becomes necessary when the injection-grade Zhichuan API exhibits segregation in bulk packaging or when its specific surface area creates dust exposure risks on the filling line. High-shear granulation is performed in a top-drive mixer with an impeller tip speed of 2–3 m/s and a chopper speed of 1,500–3,000 rpm. A binder solution of povidone K30 at 5–8% w/w is sprayed at 15–25% w/w of the dry powder mass over 3–8 min. The endpoint is not fixed by time alone; the granulation is stopped when impeller power draw or torque reaches a plateau corresponding to a wet-mass density of 0.55–0.75 g/mL. Over-wetting beyond this range produces large agglomerates above 1.6 mm and increases the downstream drying load. The wet granules are transferred to a fluid-bed dryer; inlet air temperature is set at 60–70°C and product temperature held at 40–45°C until loss-on-drying reaches 1.0–2.5% w/w. Dried granules are passed through a 1.0 mm or 1.6 mm oscillating sieve and blended with crospovidone 3–5% w/w and sodium stearyl fumarate 0.5–1.5% w/w. Content uniformity is assessed according to Ph. Eur. 2.9.40 on 10 composite samples; the acceptance value should be ≤15. Granules are filled into 1 g or 5 g sachets of polyester-aluminium-polyethylene laminate; the moisture barrier layer limits water vapour transmission to below 0.1 g/m²/day. Terminal granule presentations are intended for oral administration after mixing with feed or for direct drenching in small ruminants.

Dry powder presentations for drinking water and oral drench reconstitution require segregation-resistant blending rather than aggressive size reduction of the Zhichuan Injection Veterinary Grade API. The injection-grade material is first sifted through a 500 µm stainless-steel screen to remove agglomerates; then a 1:10 geometric pre-dilution with dextrose monohydrate or lactose monohydrate is prepared. The pre-dilution step reduces the risk of high-potency pockets in the final powder because the active particle distribution is not uniform enough for direct addition. Final blending takes place in a double-ribbon mixer or V-blender at 60–70% vessel fill for 10–25 min, depending on the bulk density difference between the API and carrier. Blend uniformity is confirmed by sampling 10 points across the mixer; the relative standard deviation for assay should be ≤5% and individual values should fall within 90.0–110.0% of the declared content. The powder is filled into 100 g and 1 kg high-density polyethylene pouches with foil-lined seals. If the powder is intended for drinking-water administration, solubility or dispersibility is verified in hard water at 500 ppm calcium carbonate hardness; complete dispersion should occur within 5 min under gentle stirring at 20–25°C. The terminal product is labelled for reconstitution at a defined concentration, commonly 1 g/L or 5 g/L in stock solutions, but the registered dilution is species- and indication-dependent. Validated cleaning procedures for the mixer follow 21 CFR 211.67 and require residue verification by swab or rinse sampling.

Carryover Control, Geometric Dilution, and Type A Medicated Article Limits

In medicated feed premix production, the Zhichuan Injection Veterinary Grade API must be converted into a homogenous Type A medicated article before it is introduced into complete feed. The process begins with carrier selection: calcium carbonate, corn cob meal, or wheat middlings are chosen to match the bulk density of the active powder within 0.05 g/mL so that segregation during bag filling and transport is reduced. Geometric dilution is performed in three stages: the first stage blends one part API with nine parts carrier for 10 min; the second stage combines the first dilution with additional carrier to reach 1:100; the final stage brings the mixture to the registered premix potency, typically 2%, 5%, or 10% w/w active depending on the species and indication. Mixing is conducted in a double-ribbon mixer or paddle mixer at 60–80% of working volume for 10–20 min. Homogeneity of the premix is measured by taking 10 samples at top, middle, and bottom zones; the coefficient of variation should be ≤5% for the active and ≤3% for the carrier marker if one is used. The premix is packed in 25 kg multiwall paper bags with an inner polyethylene liner. Cross-contamination control follows EU Regulation 2019/4 for medicated feed; where the API is an antimicrobial or another restricted substance, the carryover into the first non-target batch must be validated below the substance-specific legal threshold or the analytical limit of quantification, whichever is lower. In the United States, 21 CFR Part 225 and 21 CFR Part 226 govern medicated feed manufacturing and Type A medicated articles; equipment cleaning and sequencing records are required under 21 CFR 211.67. The exact legal carryover ceiling must be taken from the registration dossier because published data for this specific configuration is limited. The terminal premix is not administered directly; it is incorporated into complete feed at an inclusion rate of 0.5–5 kg per tonne and mixed again in the feed mill to a target coefficient of variation of ≤5%.

Across these downstream forms, the following compendial test matrix separates the release tests that are most sensitive to the conversion route for Zhichuan Injection Veterinary Grade API. The acceptance column lists harmonisation targets or default internal limits; registered monographs supersede these values where they exist.

Oral solution and drench formulations of Zhichuan Injection Veterinary Grade API are compounded by first fixing the pH of the bulk vehicle before the active is added, because pH excursions during active dissolution can shift the ionisation state and reduce recovery. Purified water is charged into a jacketed stainless-steel vessel and heated to 30–40°C; a buffer system of citrate or acetate at 5–20 mM is then dissolved. Preservatives are added to the cooled bulk when required: sodium benzoate at 0.1–0.2% w/w or potassium sorbate at 0.1–0.2% w/w are common for multidose oral solutions. The injection-grade API is added under high-shear agitation at 500–1,000 rpm until visual dissolution; dissolution time is recorded because extended wetting of high-dose formulations can indicate the need for a co-solvent such as propylene glycol at 5–15% w/w. The pH is adjusted to the registered value, typically pH 3.0–6.0, with hydrochloric acid or sodium hydroxide. The solution is filtered through a 5 µm or 10 µm polypropylene cartridge to remove insoluble particles, then filled into 100 mL, 1 L, or 5 L high-density polyethylene containers with tamper-evident closures. Clarity is inspected visually against a black and white background according to Ph. Eur. 2.9.20; the solution must be clear or only slightly opalescent. Assay is controlled at 95.0–105.0% of label claim, and the finished product is stored at controlled room temperature 15–25°C unless stability data support a wider range. For drench applications in ruminants, the product is packaged with a graduated dosing chamber or connected to an automatic drenching gun calibrated to deliver 2–5 mL per 50 kg body weight depending on the registered dose.